儿童甲状腺半切除术后甲状腺功能研究
这项回顾性队列研究纳入1998至2023年间在一个儿童甲状腺中心接受甲状腺半切除术的136例患者(85%为女性),中位手术年龄15.4岁。主要结局为持续性甲状腺功能减退(TSH≥5 mIU/L)或接受左甲状腺素(LT4)治疗,5年估计风险为27.5%。术前TSH≥2 mIU/L(尤其合并TPO抗体阳性)可识别高风险患儿。
要点
- 儿童半甲状腺切除术后5年内持续甲减或LT4治疗风险为27.5%,多发生于术后第一年。
- 术前TSH≥2 mIU/L者5年风险58.8%,<2 mIU/L者12.8%;TPO抗体阳性独立增加风险(OR 7.37)。
- 一过性甲减发生率为16%,可能无需治疗。
核心结论
- 儿童半甲状腺切除术后5年内持续甲减或LT4治疗发生率为27.5%,多数在术后12个月内出现。
- 术前TSH<2 mIU/L提示低风险,术前TSH≥2 mIU/L尤其合并TPO抗体提示高风险。
研究设计与样本
- 回顾性队列研究,纳入1998至2023年在一个儿童甲状腺中心接受半甲状腺切除术的连续儿科患者(<19岁),共136例,85%为女性,中位手术年龄15.4岁(范围0.14-19.0岁)。
- 术后甲状腺功能中位随访1.10年(IQR 0.15-3.2),LT4治疗状态中位随访1.76年(IQR 0.38-4.3)。
- 采用单变量和多变量生存分析及逻辑回归评估临床特征与结局的关联。
主要发现
- 主要复合结局(持续甲减TSH≥5 mIU/L或LT4治疗)发生于27/136例(20%),1年估计风险18.1%[CI:12.1-26.6%],5年估计风险27.5%[CI:18.7-39.2%]。
- 27例复合结局中21例(78%)发生在12个月内,6例(22%)发生在12个月后。
- 复合结局与术前TSH相关(风险比1.89[CI:1.31-2.74],p=0.001);术前TSH≥2 mIU/L区分高(58.8%)与低(12.8%)5年风险,ROC曲线下面积0.73[CI:0.60-0.85]。
- TPO抗体阳性独立增加复合结局风险(OR:7.37[CI:1.09-49.9],p=0.041)。
- 持续性甲减发生于14/128例(11%),5年估计风险12.9%[CI:7.7-21.1%];严重甲减5/136例(3.7%);一过性甲减22/136例(16%)。
关键数值与推荐
- 持续甲减定义为TSH≥5 mIU/L。
- 术前TSH≥2 mIU/L为高风险阈值,术前TSH<2 mIU/L为低风险阈值。
临床怎么用
- 术前应使用术前TSH和TPO抗体状态进行风险分层咨询。
- 术后第一年应密切监测甲状腺功能,尤其对术前TSH≥2 mIU/L或TPO抗体阳性患儿。
- 一过性甲减常见但可能无需LT4治疗。
局限性
- 回顾性研究设计。
- 单中心数据。
- 随访时间中位数较短(甲状腺功能1.10年,LT4状态1.76年)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The risk of hypothyroidism after hemithyroidectomy is not well defined in the pediatric population. We sought to determine the incidence of hypothyroidism after hemithyroidectomy in children and the clinical factors associated with this risk. METHODS: This is a retrospective cohort study of consecutive pediatric patients (<19 years of age) who underwent hemithyroidectomy in a pediatric thyroid center between 1998 and 2023, with data available on postoperative thyroid function and/or levothyroxine (LT4) treatment. The primary outcome was the composite of persistent hypothyroidism (thyrotropin [TSH] ≥ 5 mIU/L) or LT4 treatment (PersHypo/LT4). Secondary outcomes were persistent hypothyroidism and transient hypothyroidism. Univariable and multivariable survival analysis and logistic regression were used to evaluate associations of these outcomes with clinical characteristics. RESULTS: A total of 136 eligible patients (85% female) underwent hemithyroidectomy at a median (range) age of 15.4 (0.14-19.0) years. The median (interquartile range) postsurgical follow-up was 1.10 (0.15-3.2) years for thyroid function and 1.76 (0.38-4.3) years for LT4 treatment status. PersHypo/LT4 occurred in 27/136 patients (20%), with an estimated risk of 18.1% [CI: 12.1-26.6%] at 1 year and 27.5% [CI: 18.7-39.2%] at 5 years. PersHypo/LT4 occurred within 12 months in 21/27 cases (78%) and after 12 months in 6/27 (22%). PersHypo/LT4 was associated with preoperative TSH (hazard ratio 1.89, [CI: 1.31-2.74], p = 0.001), and preoperative TSH ≥ 2 mIU/L optimally distinguished patients with high (58.8%) versus low (12.8%) 5-year risk of PersHypo/LT4 (receiver operator characteristic AUC 0.73, [CI: 0.60-0.85]). The presence of thyroperoxidase (TPO) antibodies was independently associated with increased risk of PersHypo/LT4 (OR: 7.37, [CI: 1.09-49.9], p = 0.041). Persistent hypothyroidism occurred in 14/128 patients (11%), with an estimated 5-year risk of 12.9% [CI: 7.7-21.1%]. Severe hypothyroidism occurred in 5/136 patients (3.7%), and transient hypothyroidism occurred in 22/136 patients (16%). CONCLUSIONS: Persistent hypothyroidism or LT4 treatment occurs in 27.5% of children within 5 years after hemithyroidectomy, usually in the first postoperative year. Preoperative TSH < 2 mIU/L may identify children at low risk, whereas preoperative TSH ≥ 2 mIU/L, particularly in conjunction with TPO antibodies, may identify children at high risk. Transient hypothyroidism also occurs commonly but may not require treatment. These data should inform preoperative counseling and postoperative monitoring around hemithyroidectomy in children.
引用
- Adusumelli Y, Petty CR, Cherella CE, et al. Thyroid Function After Hemithyroidectomy in Children. Thyroid. 2025. PMID: 41468168. doi:10.1177/10507256251412322
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。